AR084093A1 - Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica - Google Patents
Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceuticaInfo
- Publication number
- AR084093A1 AR084093A1 ARP110104511A ARP110104511A AR084093A1 AR 084093 A1 AR084093 A1 AR 084093A1 AR P110104511 A ARP110104511 A AR P110104511A AR P110104511 A ARP110104511 A AR P110104511A AR 084093 A1 AR084093 A1 AR 084093A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- naltrexone
- buproprion
- attractions
- prepare
- Prior art date
Links
- 230000037406 food intake Effects 0.000 title abstract 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 2
- 229960003086 naltrexone Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 235000012631 food intake Nutrition 0.000 abstract 3
- 208000014679 binge eating disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010004716 Binge eating Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001058 bupropion Drugs 0.000 abstract 1
- 229940047123 bupropion and naltrexone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41935410P | 2010-12-03 | 2010-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084093A1 true AR084093A1 (es) | 2013-04-17 |
Family
ID=46172302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104511A AR084093A1 (es) | 2010-12-03 | 2011-12-02 | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica |
| ARP210103652A AR124497A2 (es) | 2010-12-03 | 2021-12-23 | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103652A AR124497A2 (es) | 2010-12-03 | 2021-12-23 | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20130252995A1 (enExample) |
| EP (1) | EP2646011B1 (enExample) |
| JP (1) | JP2014508717A (enExample) |
| KR (1) | KR20140035319A (enExample) |
| CN (1) | CN103298462A (enExample) |
| AR (2) | AR084093A1 (enExample) |
| AU (3) | AU2011336298B2 (enExample) |
| BR (1) | BR112013015957B1 (enExample) |
| CA (1) | CA2819003A1 (enExample) |
| CL (1) | CL2013001565A1 (enExample) |
| CY (1) | CY1119560T1 (enExample) |
| DK (1) | DK2646011T3 (enExample) |
| ES (1) | ES2647232T3 (enExample) |
| HR (1) | HRP20171678T1 (enExample) |
| HU (1) | HUE034641T2 (enExample) |
| IL (1) | IL226483A0 (enExample) |
| LT (1) | LT2646011T (enExample) |
| MX (1) | MX350304B (enExample) |
| NO (1) | NO2646011T3 (enExample) |
| PL (1) | PL2646011T3 (enExample) |
| PT (1) | PT2646011T (enExample) |
| RS (1) | RS56548B1 (enExample) |
| RU (1) | RU2620913C2 (enExample) |
| SI (1) | SI2646011T1 (enExample) |
| SM (1) | SMT201700537T1 (enExample) |
| TW (2) | TWI536986B (enExample) |
| WO (1) | WO2012075453A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| DE602007005402D1 (de) | 2006-11-09 | 2010-04-29 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
| GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20100317572A1 (en) * | 2007-12-20 | 2010-12-16 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
| KR102385359B1 (ko) * | 2010-11-08 | 2022-04-11 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
-
2011
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 SM SM20170537T patent/SMT201700537T1/it unknown
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en not_active Ceased
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Withdrawn
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| Colla et al. | Involvement of monoaminergic systems in the antidepressant-like effect of Eugenia brasiliensis Lam.(Myrtaceae) in the tail suspension test in mice | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
| MX344303B (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| DK1778680T3 (da) | Spirocykliske cyclohexaderivater | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| AR063497A1 (es) | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |